Food and Drug Administration's Obesity Drug Guidance Document: A Short History.
Summary of "Food and Drug Administration's Obesity Drug Guidance Document: A Short History."
No Summary Available
Affiliation
Division of Metabolism and Endocrinology Products, Office of Drug Evaluation II, Center for Drug Evaluation and Research, US Food and Drug Administration, Bldg 22, Room 3360, 10903 New Hampshire Ave, Silver Spring, MD 20993. eric.colman@fda.hhs.gov.
Journal Details
This article was published in the following journal.
Name: Circulation
ISSN: 1524-4539
Pages: 2156-64
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22547756
- DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.111.028381
Medical and Biotech [MESH] Definitions
Drug Resistance
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
Drug Tolerance
Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL.
Drug Administration Schedule
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Pulse Therapy, Drug
Administration of high doses of pharmaceuticals over short periods of time.
Drug Carriers
Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.
PubMed Articles
The Food and Drug Administration (FDA) is reclassifying the device type, standard percutaneous transluminal coronary angioplasty (PTCA) catheters, from class III (premarket approval) into class II (sp...
Clinical pharmacology as a cornerstone of orphan drug development.
A recent US Food and Drug Administration (FDA) advisory committee meeting highlighted the potential of clinical pharmacology to overcome challenges in orphan drug development.
Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease.
The focus of drug development in Alzheimer's disease has increasingly been on earlier disease stages, before overt dementia, when it is difficult to assess cognitive impairment. The FDA has now develo...
Clinical Trials
The purpose of this study is to test the safety of a combination of two anticancer medicines, called vorinostat and etoposide, with a high dose of a vitamin called niacinamide. These medic...
The purpose of this study is to find out whether or not the addition of hydroxyurea to didanosine (ddI) and other anti-HIV medications will result in better control of HIV infection....
Sleep Deprivation and Energy Balance
Observational and epidemiological studies have found a link between obesity and short sleep duration with the prevalence of both increasing in the past decades. At this time, it is unknow...
Effect of Yohimbine on Colon Transit
This study is being done to learn if yohimbine, a naturally occurring drug, affects the speed at which food travels through the stomach, intestines and colon, and if yohimbine affects the...
Pravastatin (Pravachol) is approved by the Food and Drug Administration (FDA) and is used to treat high cholesterol. Darunavir (Prezista) and ritonavir (Norvir) are approved by the Food a...
